Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P09769
UPID:
FGR_HUMAN
Alternative names:
Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog; Proto-oncogene c-Fgr; p55-Fgr; p58-Fgr; p58c-Fgr
Alternative UPACC:
P09769; D3DPL7; Q9UIQ3
Background:
Tyrosine-protein kinase Fgr, known by its aliases such as Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog and Proto-oncogene c-Fgr, plays a pivotal role in immune response regulation. It influences neutrophil, monocyte, macrophage, and mast cell functions, alongside cytoskeleton remodeling, phagocytosis, cell adhesion, and migration. Fgr acts downstream of various receptors, regulating actin cytoskeleton reorganization and cellular responses to external stimuli.
Therapeutic significance:
Understanding the role of Tyrosine-protein kinase Fgr could open doors to potential therapeutic strategies.